BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16755224)

  • 1. Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia.
    Gowda A; Byrd JC
    Curr Opin Hematol; 2006 Jul; 13(4):266-72. PubMed ID: 16755224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies.
    Montillo M; Hamblin T; Hallek M; Montserrat E; Morra E
    Haematologica; 2005 Mar; 90(3):391-9. PubMed ID: 15749671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification in chronic lymphocytic leukemia.
    Seiler T; Döhner H; Stilgenbauer S
    Semin Oncol; 2006 Apr; 33(2):186-94. PubMed ID: 16616065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.
    Maloum K; Settegrana C; Chapiro E; Cazin B; Leprêtre S; Delmer A; Leporrier M; Dreyfus B; Tournilhac O; Mahe B; Nguyen-Khac F; Lesty C; Davi F; Merle-Béral H
    Ann Hematol; 2009 Dec; 88(12):1215-21. PubMed ID: 19340428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic lesions in chronic lymphocytic leukemia: clinical implications.
    Montserrat E; Moreno C
    Curr Opin Oncol; 2009 Nov; 21(6):609-14. PubMed ID: 19713841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
    Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
    Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic markers in chronic lymphocytic leukaemia.
    Hamblin TJ
    Best Pract Res Clin Haematol; 2007 Sep; 20(3):455-68. PubMed ID: 17707833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia.
    Kharfan-Dabaja MA; Chavez JC; Khorfan KA; Pinilla-Ibarz J
    Cancer; 2008 Sep; 113(5):897-906. PubMed ID: 18618518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Ilaria Del Principe M; Buccisano F; Maurillo L; Niscola P; Venditti A; Amadori S
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1787-800. PubMed ID: 17181492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic factors in chronic lymphocytic leukaemia: contribution of recent biological markers].
    Evrard S; Gaussem P; Helley D; Darnige L
    Ann Biol Clin (Paris); 2005; 63(6):589-97. PubMed ID: 16330377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia.
    Ertault-Daneshpouy M; Noguera ME; Gisselbrecht C; Haddad A; Brice P; Marolleau JP; Soulier J; Mounier N
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):55-63. PubMed ID: 18322442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
    Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC
    J Clin Oncol; 2007 Mar; 25(7):799-804. PubMed ID: 17283363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell CD38 expression in B-chronic lymphocytic leukaemia.
    Abousamra NK; El-Din MS; Azmy E
    Hematol Oncol; 2009 Jun; 27(2):82-9. PubMed ID: 19247976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging therapy for chronic lymphocytic leukaemia.
    Auer RL; Gribben J; Cotter FE
    Br J Haematol; 2007 Dec; 139(5):635-44. PubMed ID: 17961187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA-based markers as prognostic factors in chronic lymphocytic leukemia.
    Sevov M; Rosenquist R; Mansouri L
    Expert Rev Hematol; 2012 Feb; 5(1):69-79. PubMed ID: 22272707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of symptomatic, untreated chronic lymphocytic leukemia.
    Kasamon YL; Flinn IW
    Blood Rev; 2007 May; 21(3):143-56. PubMed ID: 17097783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors.
    Rossi D; Sozzi E; Puma A; De Paoli L; Rasi S; Spina V; Gozzetti A; Tassi M; Cencini E; Raspadori D; Pinto V; Bertoni F; Gattei V; Lauria F; Gaidano G; Forconi F
    Br J Haematol; 2009 Jun; 146(1):64-75. PubMed ID: 19438485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia.
    Santos ES; Masri M; Safah H
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):875-91. PubMed ID: 16221057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia.
    Hewamana S; Lin TT; Rowntree C; Karunanithi K; Pratt G; Hills R; Fegan C; Brennan P; Pepper C
    J Clin Oncol; 2009 Feb; 27(5):763-9. PubMed ID: 19124804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
    Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
    Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.